TRI-LEGEST 21 Drug Patent Profile
✉ Email this page to a colleague
When do Tri-legest 21 patents expire, and when can generic versions of Tri-legest 21 launch?
Tri-legest 21 is a drug marketed by Barr and is included in one NDA.
The generic ingredient in TRI-LEGEST 21 is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
Summary for TRI-LEGEST 21
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 5 |
Patent Applications: | 172 |
Formulation / Manufacturing: | see details |
DailyMed Link: | TRI-LEGEST 21 at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for TRI-LEGEST 21
US Patents and Regulatory Information for TRI-LEGEST 21
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Barr | TRI-LEGEST 21 | ethinyl estradiol; norethindrone acetate | TABLET;ORAL-21 | 076405-001 | Oct 26, 2007 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |